Analyst Reco. Exagen Inc.

Equities

XGN

US30068X1037

Market Closed - Nasdaq Other stock markets 02:00:01 27/04/2024 am IST			5-day change	1st Jan Change
1.412 ^USD	+0.15%		+3.07%	-29.04%

26/04	Exagen Inc. Announces Changes in Board of Directors	CI
18/03	Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Adjusts Price Target on Exagen to $5 From $6, Maintains Buy Rating	22/23/22	MT
BTIG Adjusts Exagen's Price Target to $7 From $10, Keeps Buy Rating	17/22/17	MT
Canaccord Genuity Cuts Price Target on Exagen to $7 From $8, Affirms Buy Rating	15/22/15	MT
KeyBanc Downgrades Exagen to Sector Weight From Overweight, Citing 'Uncertain Test Pricing Process'	05/22/05	MT
KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating	13/22/13	MT
KeyBanc Adjusts Exagen's Price Target to $20 From $30, Reiterates Overweight Rating	25/22/25	MT
Cowen Adjusts Exagen's Price Target to $16 from $26, Reiterates Outperform Rating	23/22/23	MT
KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating	11/21/11	MT
EXAGEN : BTIG Adjusts Exagen's Price Target to $20 From $23, Reiterates Buy Rating	10/21/10	MT
EXAGEN : Canaccord Genuity Initiates Exagen at Buy Rating With $25 Price Target	15/21/15	MT
EXAGEN : KeyBanc Initiates Exagen at Overweight with $32 Price Target	10/20/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer